| --- | --- | --- | --- | --- | --- | |-------|-------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | On Today's Earnings Call | --- | --- | --- | --- | |--------------------------------------------|--------------------|-------------------------------------|--------------------------------------------------------------------| | | | | | | | | | | | Brett Monia, Ph.D. Chief Executive Officer | | Beth Hougen Chief Financial Officer | Richard Geary, Ph.D. Executive Vice President, De ...

IONIS" FY 2020 Financial Results and Business Update February 24, 2021 On Today's Earnings Call | --- | --- | --- | --- | |--------------------------------------------|--------------------|-------------------------------------|--------------------------------------------------------------------| | | | | | | | | | | | Brett Monia, Ph.D. Chief Executive Officer | | Beth Hougen Chief Financial Officer | Richard Geary, Ph.D. Executive Vice President, Development | | | Eric Swayze, Ph.D. | Executive Vice Preside ...

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q4 2020 Earnings Conference Call February 24, 2020 9:00 AM ET Company Participants Wade Walke - VP, IR Brett Monia - CEO Beth Hougen - CFO Richard Geary - EVP of Development Onaiza Cadoret - Chief Corporate Development and Commercial Officer Eric Swayze - EVP of Research Conference Call Participants Yaron Werber - Cowen Alex Thompson - Stifel Jim Birchenough - Wells Fargo Tyler Van Buren - Piper Sandler Vincent Chen - Bernstein Joel Beatty - Citi Yale Jen - Laidlaw ...

IONIS" Investor Day 2020 December 7, 2020 Forward Looking Language Statement This presentation includes forward-looking statements regarding our business, financial guidance and the therapeutic and commercial potential of SPINRAZA® (nusinersen), TEGSEDI® (inotersen), WAYLIVRA® (volanesorsen) and Ionis' technologies and products in development, including the business of Akcea Therapeutics, Inc., Ionis' wholly owned subsidiary. Any statement describing Ionis' goals, expectations, financial or other projection ...

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q3 2020 Earnings Conference Call November 4, 2020 11:30 AM ET Company Participants Wade Walke – Vice President of Investor Relations Brett Monia – Chief Executive Officer Beth Hougen – Chief Financial Officer Onaiza Cadoret – Chief Corporate Development and Commercial Officer Richard Geary – Executive Vice President of Development Eric Swayze – Executive Vice President of Research Kyle Jenne – Chief Commercial Officer-Akcea Conference Call Participants Do Kim – BMO ...

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q2 2020 Earnings Conference Call August 5, 2020 11:30 AM ET Company Participants Wade Walke - Vice President of Investor Relations Brett Monia - Chief Executive Officer Beth Hougen - Chief Financial Officer Richard Geary - Executive Vice President of Development Onaiza Cadoret - Chief Corporate Development & Commercial Officer Conference Call Participants Jim Birchenough - Wells Fargo Ellie Merle - Cantor Fitzgerald Chad Messer - Needham & Company Tyler Van Buren - ...

IONIS® Neurology Webcast July 14, 2020 Forward Looking Language Statement This presentation includes forward-looking statements regarding our business, financial guidance and the therapeutic and commercial potential of SPINRAZA® (nusinersen) and Ionis' technologies and products in development, including Ionis' neurology franchise. Any statement describing Ionis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk state ...

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) BMO 2020 Prescriptions for Success Healthcare Conference June 23, 2020 2:00 PM ET Company Participants Eric Swayze - SVP of Research Wade Walke - Head, IR Conference Call Participants Do Kim - BMO Capital Markets Do Kim Good afternoon. My name is Do Kim. I'm one of the Biotech Analyst at BMO. For next fireside chat, we have with us, Eric Swayze, SVP Research at Ionis Pharmaceuticals and Wade Walke, Head of Investor Relations. Could you start by providing us a brief ...